4D Molecular Therapeutics Inc

NASDAQ:FDMT   3:59:55 PM EDT
7.37
-0.03 (-0.40%)
Other Pre-Announcement

4D Molecular Therapeutics Reports Q1 2022 Results And Provides Corporate Updates

Published: 05/12/2022 20:10 GMT
4D Molecular Therapeutics Inc (FDMT) - 4d Molecular Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Updates.
Q1 Revenue $1.2 Million.
Qtrly Loss per Share $0.82.
4d Molecular Therapeutics - Expect Current Cash, Equivalents & Marketable Securities to Be Sufficient to Fund Operations Into Second Half of 2024.